Citigroup Inc Praxis Precision Medicines, Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.87 - $1.71 $72,148 - $141,808	82,929 Added 44585.48%	83,115 $142,000
Q2 2023 Aug 10, 2023	SELL	$0.83 - $1.18 $1,330 - $1,891	-1,603 Reduced 89.6%	186 $0
Q1 2023 May 11, 2023	SELL	$0.8 - $4.98 $213 - $1,329	-267 Reduced 12.99%	1,789 $1,000
Q4 2022 Feb 09, 2023	SELL	$1.88 - $2.49 $13,953 - $18,480	-7,422 Reduced 78.31%	2,056 $4,000
Q3 2022 Nov 10, 2022	SELL	$2.5 - $4.77 $585,227 - $1.12 Million	-234,091 Reduced 96.11%	9,478 $22,000

Q2 2022 Aug 10, 2022	BUY	$1.75 - $11.34 $373,248 - $2.42 Million	213,285 Added 704.28%	243,569 $597,000
Q1 2022 May 12, 2022	SELL	$10.21 - $20.29 $514,390 - $1.02 Million	-50,381 Reduced 62.46%	30,284 $309,000
Q4 2021 Feb 10, 2022	BUY	$16.76 - $22.99 $713,138 - $978,224	42,550 Added 111.64%	80,665 $1.59 Million
Q3 2021 Nov 10, 2021	BUY	$13.15 - $22.56 $501,212 - $859,874	38,115 New	38,115 $705,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.79B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.